Assessing the potential outcomes of achieving the World Health Organization global non-communicable diseases targets for risk factors by 2025: is there also an economic dividend?


Journal

Public health
ISSN: 1476-5616
Titre abrégé: Public Health
Pays: Netherlands
ID NLM: 0376507

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 11 04 2018
revised: 20 10 2018
accepted: 04 02 2019
pubmed: 17 3 2019
medline: 22 5 2019
entrez: 17 3 2019
Statut: ppublish

Résumé

This study assesses the change in premature mortality and in morbidity under the scenario of meeting the World Health Organization (WHO) global targets for non-communicable disease (NCD) risk factors (RFs) by 2025 in France. It also estimates medical expenditure savings because of the reduction of NCD burden. A microsimulation model is used to predict the future health and economic outcomes in France. A 'RF targets' scenario, assuming the achievement of the six targets on RFs by 2025, is compared to a counterfactual scenario with respect to disability-adjusted life years and healthcare costs differences. The achievement of the RFs targets by 2025 would save about 25,300 (and 75,500) life years in good health in the population aged 25-64 (respectively 65+) years on average every year and would help to reduce healthcare costs by about €660 million on average per year, which represents 0.35% of the current annual healthcare spending in France. Such a reduction in RFs (net of the natural decreasing trend in mortality) would contribute to achieving about half of the 2030 NCD premature mortality target in France. The achievement of the RF targets would lead France to save life years and life years in good health in both working-age and retired people and would modestly reduce healthcare expenditures. To achieve RFs targets and to curb the growing burden of NCDs, France has to strengthen existing and implement new policy interventions.

Identifiants

pubmed: 30876722
pii: S0033-3506(19)30033-2
doi: 10.1016/j.puhe.2019.02.009
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

173-179

Informations de copyright

Copyright © 2019 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.

Auteurs

M Devaux (M)

Health Division, Organization for Economic Co-operation and Development, Paris, France.

A Lerouge (A)

Health Division, Organization for Economic Co-operation and Development, Paris, France.

B Ventelou (B)

Aix-Marseille School of Economics, Aix-Marseille University, Marseille, France.

Y Goryakin (Y)

Health Division, Organization for Economic Co-operation and Development, Paris, France.

A Feigl (A)

Health Division, Organization for Economic Co-operation and Development, Paris, France.

S Vuik (S)

Health Division, Organization for Economic Co-operation and Development, Paris, France.

M Cecchini (M)

Health Division, Organization for Economic Co-operation and Development, Paris, France. Electronic address: michele.cecchini@oecd.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH